- Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus. Germany > Frankfurt
RESEARCH PROFILE: First Stage Researcher (R1)
APPLICATION DEADLINE: Sept 20th, 2023
EU RESEARCH FRAMEWORK PROGRAMME: HORIZON 2020
MARIE SKŁODOWSKA-CURIE GRANT AGREEMENT NUMBER: 953407
Job Offer Title: PhD position to explore the role of the tumor microenvironment in myelodysplastic syndromes using 3D human organotypic models
The Marie Skłodowska-Curie Innovative Training Network (MSCA-ITN) “INTERCEPT-MDS – “Exploring cell-to-cell heterogeneity and exploiting epigenetic regulation for the interception of myeloid disease cells" is offering 1 PhD position, to join the laboratory of Dr. Hind Medyouf, at the Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, in Frankfurt (Germany).
INTERCEPT-MDS is funded by the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 953407. See more info about H2020 MSCA ITNs at: https://marie-sklodowska-curie-actions.ec.europa.eu/funding/marie-sklodowska-curie-innovative-training-networks-2020.
PhD Project 9: Exploiting 3D organotypic niche models to dissect the cellular crosstalk between niche and haematopoietic stem/progenitor cells (HSPCs) in human myelodysplastic syndromes (MDS): This ongoing scientific project focuses on MDS, a heterogenous group of pre-leukemic diseases where pre-malignant stem cells show a great dependency on their surrounding niche cells (Medyouf, Cell Stem Cell, 2014; Mossner, Blood, 2016; Medyouf, Blood, 2017). The PhD candidate will dissect the molecular mechanisms and cellular interactions that underpin this dependency and leverage the gained knowledge for the rational design of innovative niche-directed therapeutic approaches that enable disease interception. To achieve this, the PhD applicant will apply cutting-edge technologies (e.g., single cell omics, CRISPR screening) in the context of a fully human 3D organotypic bone marrow model (3D Human Organotypic Marrow Environment or 3D HOME), recently established by the Medyouf lab. The PhD candidate will initially expand the throughput and standardization of the 3DHOMEs system, two essential features that will facilitate its use as a powerful screening platform. Results obtained from the 3DHOMEs will be validated using patient samples and patient-derived xenograft models.
To broaden the expertise of the PhD candidate and support the project, two secondments (stays in collaborating laboratories within the network) will be offered as an integral part of the PhD project. The envisioned secondments for this position are at GenomeScan B.V. to gain in depth expertise in NGS analysis (Leiden, The Netherlands) and at INSERM, to perform functional CRISPR screening (Paris, France).
About the INTERCEPT-MDS network
INTERCEPT-MDS brings together 10 European public and private institutions in a European network of experts in leukaemia, epigenetics and single-cell approaches. The PhD candidate will have eleven counterparts at other leading European research institutions. The secondments in other European institutions within the network will provide the needed interactions to achieve research and training excellence and improve the future career perspectives of the fellow. For further information on the INTERCEPT-MDS network, including past and future events, please visit www.intercept-mds.eu.